1. A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. (October 2018) Authors: Yerushalmi, Rinat; Eiermann, Wolfgang; Rugo, Hope; Ettl, Johannes; Hurvitz, Sara A.; Gonçalves, Anthony; Miguel, Martin; Markova, Denka; Tudor, Iulia; Blum, Joanne; Hannah, Alison; Litton, Jennifer Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗